{"id":61999,"date":"2026-03-31T19:46:48","date_gmt":"2026-03-31T11:46:48","guid":{"rendered":"https:\/\/flcube.com\/?p=61999"},"modified":"2026-03-31T19:46:49","modified_gmt":"2026-03-31T11:46:49","slug":"mercks-oral-pcsk9-inhibitor-enlicitide-shows-superior-ldl-c-reduction-in-coralreef-addon-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61999","title":{"rendered":"Merck&#8217;s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial"},"content":{"rendered":"\n<p><strong>Merck &amp; Co., Inc.<\/strong> (MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>) has disclosed detailed results from the <strong>CORALreef AddOn study<\/strong>, demonstrating that its investigational <strong>oral macrocyclic peptide enlicitide decanoate<\/strong> achieved <strong>statistically significant and clinically meaningful reductions<\/strong> in low-density lipoprotein cholesterol (LDL-C) compared to existing oral non-statin therapies in patients with hypercholesterolemia at risk for atherosclerotic cardiovascular disease (ASCVD).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-summary\">Clinical Trial Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Name<\/strong><\/td><td>CORALreef AddOn<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Active-controlled trial<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adults with hypercholesterolemia who have or are at risk for ASCVD on background statin therapy<\/td><\/tr><tr><td><strong>Comparator Arm<\/strong><\/td><td>Bempedoic acid, ezetimibe, or combination therapy<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>LDL-C reduction at 8 weeks (day 56)<\/td><\/tr><tr><td><strong>Key Finding<\/strong><\/td><td>Statistically significant and clinically meaningful LDL-C reductions vs. control<\/td><\/tr><tr><td><strong>Secondary Endpoint<\/strong><\/td><td>LDL-C target attainment rates \u2013 significantly higher in enlicitide arm<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-profile\">Mechanism of Action Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class:<\/strong> Investigational novel macrocyclic peptide<\/li>\n\n\n\n<li><strong>Target:<\/strong> PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Binds to PCSK9 and inhibits its interaction with LDL receptor<\/li>\n\n\n\n<li><strong>Biological Effect:<\/strong> Increases LDL receptors available on cell surfaces to clear cholesterol from blood<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Oral tablet \u2013 first oral therapy with same mechanism as injectable monoclonal antibodies<\/li>\n\n\n\n<li><strong>Therapeutic Innovation:<\/strong> Combines proven PCSK9 inhibition biology with convenient oral delivery<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-differentiation-analysis\">Competitive Differentiation Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Enlicitide Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Delivery Method<\/strong><\/td><td>Oral tablet vs. injectable monoclonal antibodies (Repatha, Praluent)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Same proven PCSK9 inhibition as approved injectables<\/td><\/tr><tr><td><strong>Convenience<\/strong><\/td><td>Eliminates need for subcutaneous injections every 2-4 weeks<\/td><\/tr><tr><td><strong>Compliance<\/strong><\/td><td>Potential for improved patient adherence with oral dosing<\/td><\/tr><tr><td><strong>Market Position<\/strong><\/td><td>First-in-class oral PCSK9 inhibitor if approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The development represents a potential paradigm shift in PCSK9 inhibition, addressing the major limitation of current therapies \u2013 the requirement for regular injections.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-assessment\">Market Impact Assessment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stakeholder<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>High-Risk Cardiovascular Patients<\/strong><\/td><td>Access to highly effective LDL-C lowering without injection burden<\/td><\/tr><tr><td><strong>Healthcare Providers<\/strong><\/td><td>Simplified treatment algorithms with oral PCSK9 option<\/td><\/tr><tr><td><strong>Payers<\/strong><\/td><td>Potential cost-effectiveness through improved adherence and reduced administration costs<\/td><\/tr><tr><td><strong>Merck Commercial Strategy<\/strong><\/td><td>Entry into USD 2+ billion PCSK9 inhibitor market with differentiated oral product<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Disrupts established injectable PCSK9 market dominated by Amgen and Sanofi\/Regeneron<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Approximately 30-40% of high-risk cardiovascular patients fail to achieve LDL-C targets on statins alone, representing a substantial addressable market for effective add-on therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook\">Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Pathway:<\/strong> Positive Phase III data supports NDA\/BLA submission for accelerated approval<\/li>\n\n\n\n<li><strong>Commercial Launch:<\/strong> Potential 2027 launch timeline if regulatory process proceeds smoothly<\/li>\n\n\n\n<li><strong>Market Penetration:<\/strong> Oral delivery could capture significant share from both injectable PCSK9 inhibitors and less effective oral alternatives<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Success validates Merck&#8217;s macrocyclic peptide platform for other therapeutic targets<\/li>\n\n\n\n<li><strong>Global Opportunity:<\/strong> Worldwide commercial rights provide multi-billion dollar revenue potential<\/li>\n<\/ul>\n\n\n\n<p>The CORALreef AddOn results position enlicitide as a potential blockbuster therapy that could redefine standard of care for high-risk hypercholesterolemia patients.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Merck&#8217;s clinical development plans and enlicitide&#8217;s therapeutic potential. Actual regulatory approvals and commercial outcomes may differ based on further clinical data and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. (MSD, NYSE: MRK) has disclosed detailed results from the CORALreef AddOn&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,69,2675,176,903],"class_list":["post-61999","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-cvd","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck&#039;s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck &amp; Co., Inc. (MSD, NYSE: MRK) has disclosed detailed results from the CORALreef AddOn study, demonstrating that its investigational oral macrocyclic peptide enlicitide decanoate achieved statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to existing oral non-statin therapies in patients with hypercholesterolemia at risk for atherosclerotic cardiovascular disease (ASCVD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61999\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck&#039;s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (MSD, NYSE: MRK) has disclosed detailed results from the CORALreef AddOn study, demonstrating that its investigational oral macrocyclic peptide enlicitide decanoate achieved statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to existing oral non-statin therapies in patients with hypercholesterolemia at risk for atherosclerotic cardiovascular disease (ASCVD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61999\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T11:46:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T11:46:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61999#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61999\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck&#8217;s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial\",\"datePublished\":\"2026-03-31T11:46:48+00:00\",\"dateModified\":\"2026-03-31T11:46:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61999\"},\"wordCount\":484,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"CVD\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61999#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61999\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61999\",\"name\":\"Merck's Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-31T11:46:48+00:00\",\"dateModified\":\"2026-03-31T11:46:49+00:00\",\"description\":\"Merck & Co., Inc. (MSD, NYSE: MRK) has disclosed detailed results from the CORALreef AddOn study, demonstrating that its investigational oral macrocyclic peptide enlicitide decanoate achieved statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to existing oral non-statin therapies in patients with hypercholesterolemia at risk for atherosclerotic cardiovascular disease (ASCVD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61999#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61999\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61999#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck&#8217;s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck's Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Merck & Co., Inc. (MSD, NYSE: MRK) has disclosed detailed results from the CORALreef AddOn study, demonstrating that its investigational oral macrocyclic peptide enlicitide decanoate achieved statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to existing oral non-statin therapies in patients with hypercholesterolemia at risk for atherosclerotic cardiovascular disease (ASCVD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61999","og_locale":"en_US","og_type":"article","og_title":"Merck's Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial","og_description":"Merck & Co., Inc. (MSD, NYSE: MRK) has disclosed detailed results from the CORALreef AddOn study, demonstrating that its investigational oral macrocyclic peptide enlicitide decanoate achieved statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to existing oral non-statin therapies in patients with hypercholesterolemia at risk for atherosclerotic cardiovascular disease (ASCVD).","og_url":"https:\/\/flcube.com\/?p=61999","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-31T11:46:48+00:00","article_modified_time":"2026-03-31T11:46:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61999#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61999"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck&#8217;s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial","datePublished":"2026-03-31T11:46:48+00:00","dateModified":"2026-03-31T11:46:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61999"},"wordCount":484,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","CVD","Merck Sharp &amp; Dohme","MSD","NYSE: MRK"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61999#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61999","url":"https:\/\/flcube.com\/?p=61999","name":"Merck's Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-31T11:46:48+00:00","dateModified":"2026-03-31T11:46:49+00:00","description":"Merck & Co., Inc. (MSD, NYSE: MRK) has disclosed detailed results from the CORALreef AddOn study, demonstrating that its investigational oral macrocyclic peptide enlicitide decanoate achieved statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to existing oral non-statin therapies in patients with hypercholesterolemia at risk for atherosclerotic cardiovascular disease (ASCVD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61999#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61999"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61999#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck&#8217;s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61999"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61999\/revisions"}],"predecessor-version":[{"id":62000,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61999\/revisions\/62000"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}